Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2006

Micromet Nets $10M Milestone Payment from Serono

  • Micromet received a $10-million milestone payment from Serono having completed two Phase II trials with its cancer drug.  Adecatumumab (MT201) was evaluated as a single agent for the treatment of metastatic breast cancer and prostate cancer. It is a human Mab targeting tumor cells overexpressing the epithelial cell adhesion molecule.

    Micromet and Serono reported final data for the two Phase II in October. The compound originated at Micromet and is being developed in a collaboration between the companies.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »